COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00113035
Recruitment Status : Completed
First Posted : June 6, 2005
Last Update Posted : May 5, 2015
Information provided by:

Brief Summary:
Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The primary objective of this study is to identify potential candidates for future clinical studies in Pompe disease.

Condition or disease
Pompe Disease

Layout table for study information
Study Type : Observational
Enrollment : 60 participants
Time Perspective: Prospective
Official Title: Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)
Study Start Date : May 2005
Actual Study Completion Date : October 2005

Patients with late onset Pompe Disease

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must provide written informed consent prior to any study-related procedures being performed
  • Clinical presentation consistent with late-onset Pompe disease, or a current clinical diagnosis of late-onset Pompe disease
  • Must be greater than or equal to 8 years of age
  • Must be able to ambulate (use of assistive devices, such as a walker, cane or crutches, is permitted)

Exclusion Criteria:

  • Requires the use of invasive ventilatory support
  • Requires the use of noninvasive ventilatory support while awake and in an upright position
  • Use of any investigational product within 30 days prior to study enrollment
  • Unwillingness to comply with protocol requirements
  • Has clinically significant organic disease, unstable medical condition, serious or intercurrent illness
  • Is pregnant or lactating
  • Has participated in the Prospective Observational Study in Patients with Late-Onset Pompe Disease (AGLU02303, "LOPOS")

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00113035

Layout table for location information
United States, California
Tower Hematology/Oncology Medical Group
Beverly Hills, California, United States, 90211
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Missouri
Washington University Medical Center
St. Louis, Missouri, United States, 63110
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for additonal information Identifier: NCT00113035    
Other Study ID Numbers: AGLU02905
First Posted: June 6, 2005    Key Record Dates
Last Update Posted: May 5, 2015
Last Verified: May 2015
Keywords provided by Sanofi:
Glycogen Storage Disease Type II
Pompe Disease
Pompe Disease (Late-Onset)
Glycogen Storage Disease Type II (GSD-II)
Acid Maltase Deficiency
Glycogenosis 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Glycogen Storage Disease Type II
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases